We are delighted to announce that we are changing our name to Carter Morse & Goodrich.
Michael Carter, Founder and Managing Partner, commented "Our new name is in full recognition of the tremendous contribution that Ramsey Goodrich has made to our firm over the past 13 years. He is tireless not only in advising our clients but also building the firm and strengthening our reputation in the marketplace. He is an invaluable partner here at the firm and a dedicated leader in the M&A industry."
Frank Morse, Managing Director, added "While this change in name is exciting for us all, it does not change our continuing commitment to the success of our clients who are going through once-in-a lifetime transactions. We have all enjoyed working with Ramsey for years, and this recognition is well deserved."
We also recognize our continued association with Gary Mathias, who was a partner of the firm through 2015. Since 2016, Gary has served as CEO of Thetis Pharmaceuticals, a biopharmaceutical company co-founded by Gary, the partners of CMG and several ex-Pfizer R&D executives. Under Gary's leadership Thetis has raised $18 million of equity capital and grant funding, recruited a team of world class scientific and clinical advisors and advanced the development of potential first-in-class drug candidates for treatment of GI diseases. Gary has been and will continue to be a valued Senior Advisor to the CMG team.
The partners of Carter Morse & Goodrich look forward to the next 32 years of helping business owners plan, prepare, execute and ultimately close successful transactions. Please contact us if CMG can help you or your clients.